CDER and CBER Issue Guidance on Drug Trials Targeting Chronic Rhinosinusitis

In a draft guidance released yesterday, the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) offer advice for sponsors on the development of drugs or biological products for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
Source: Drug Industry Daily